Gilead to close Philadelphia and Seattle offices, make job cuts
More layoffs are hitting Gilead’s cell therapy wing, including the closure of a Philadelphia office. The company confirmed to Endpoints News that the office acquired in its Tmunity purchase is being...
View ArticleFDA says Merz's social media promotion with Nate Berkus is 'misleading'
Merz Therapeutics landed in hot water last month when the FDA said a social media promotion for its Botox rival Xeomin was “false or misleading." Now the company is trying to smooth things over. ...
View ArticlePresident-elect Trump selects Robert F. Kennedy Jr. to lead HHS
President-elect Donald Trump has picked Robert F. Kennedy Jr. to be his next HHS secretary, likely giving the government's most powerful healthcare post to a vaccine skeptic whose controversial views...
View ArticleAdaptimmune to 'redefine' itself as a sarcoma biotech, cuts a third of staffers
Adaptimmune is slashing its headcount as part of a broader company restructuring aimed at saving $300 million over the next few years through 2028. The company said it will axe 33% of its employees in ...
View ArticleALX Oncology hires Genentech, Mirati vet as CMO; After Carmot, Heather Turner...
ALX Oncology has found a new chief medical officer, tapping Alan Sandler for the role. Sandler comes to ALX from Mirati, where he was CMO before its acquisition by Bristol Myers Squibb earlier this...
View ArticleEvotec gains on Halozyme's takeover proposal
Halozyme said Thursday post-market that it wants to buy Evotec for €11 per share in cash, giving the struggling drug discoverer and manufacturer an equity value of €2 billion. Evotec's shares ...
View ArticleVitalli ends work on Daewoong asset; Alector’s $50M loan
Plus, news about Bavarian Nordic, Nuvectis Pharma, Flashpoint Therapeutics, Sparian Biosciences and TFF Pharmaceuticals: Vitalli Bio axes Daewoong asset: Vitalli, founded by Joe Jimenez’s Aditum Bio,...
View ArticleBoston Pharmaceuticals' Phase 2 MASH trial hits efficacy endpoints
Boston Pharmaceuticals succeeded on two closely watched efficacy endpoints for its Phase 2 MASH study, putting the company in contention with other biotechs seeking to treat the liver disease. The...
View ArticleEyenovia's stock falls after it halts late-stage myopia trial
Eyenovia stopped a Phase 3 trial following a review of the data that found its experimental myopia treatment wasn't going to hit the study's primary endpoint. The ophthalmic company is now considering...
View ArticleEuropean drug regulators offer wave of positive recommendations following...
The European Medicines Agency’s human medicines committee handed down a slew of positive recommendations for drugs on Friday, including Merck’s blockbuster cancer drug Keytruda and InflaRx’s monoclonal...
View ArticleWhat is the future of the Trump administration's pharmaceutical policies?
President-elect Donald Trump has just set up a showdown for the future of biopharma policy during his administration. On one side is Trump’s pick to lead the Department of Health and Human Services,
View ArticleIllumina seeks to dismiss shareholder lawsuit, denies secret $800M stake
Illumina has moved to dismiss a securities lawsuit against the company and former board members over the $8 billion Grail deal, after claiming to refute allegations around a secret financial stake that...
View ArticleTrump picks RFK Jr. for HHS; AbbVie's psych implosion; Merck tries staving...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleEisai terminated Phase 3 trial of Dravet drug lorcaserin
Eisai has stopped the Phase 3 clinical development of an adjunctive treatment for Dravet syndrome, a spokesperson confirmed to Endpoints News on Friday afternoon. The Tokyo drugmaker terminated the...
View ArticleScottish biotech Trogenix debuts with viral immunotherapy platform for cancer
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain tumor. A spinout of the University of...
View ArticleIntellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis asset
In one of the most closely-watched arenas in biotech, Intellia says its gene editing treatment for a heart muscle disease can stabilize or improve outcomes where other treatments have only been shown...
View ArticleExclusive: Athena Countouriotis' Avenzo taps Shanghai biotech for ADC, adds...
San Diego biotech Avenzo Therapeutics has in-licensed another asset, this time securing the global ex-China rights to a bispecific in the bustling antibody-drug conjugate space. Avenzo will pay up to...
View ArticleCybin reports high remission rates for psilocin drug in Phase 2 depression test
Cybin said its psilocin analog has the potential to wipe out symptoms in most patients with a serious form of depression, which marks a major step over just using antidepressants. In a small Phase 2 ...
View ArticleNovartis strikes radiopharma deal with Ratio worth up to $745M
Novartis is making another pact in radiopharma, promising as much as $745 million to a Boston-based startup. Ratio Therapeutics will get an undisclosed upfront payment as part of the exclusive...
View Article